CA2248657A1 - Peptides with increased binding affinity for hla molecules - Google Patents

Peptides with increased binding affinity for hla molecules Download PDF

Info

Publication number
CA2248657A1
CA2248657A1 CA002248657A CA2248657A CA2248657A1 CA 2248657 A1 CA2248657 A1 CA 2248657A1 CA 002248657 A CA002248657 A CA 002248657A CA 2248657 A CA2248657 A CA 2248657A CA 2248657 A1 CA2248657 A1 CA 2248657A1
Authority
CA
Canada
Prior art keywords
residues
peptide
group
peptides
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002248657A
Other languages
English (en)
French (fr)
Inventor
Alessandro Sette
Robert W. Chesnut
John Sidney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Cytel Corp
Epimmune Inc
IDM Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp, Epimmune Inc, IDM Pharma Inc filed Critical Cytel Corp
Publication of CA2248657A1 publication Critical patent/CA2248657A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002248657A 1996-03-11 1997-03-10 Peptides with increased binding affinity for hla molecules Abandoned CA2248657A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1311396P 1996-03-11 1996-03-11
US60/013,113 1996-03-11

Publications (1)

Publication Number Publication Date
CA2248657A1 true CA2248657A1 (en) 1997-09-18

Family

ID=21758378

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002248657A Abandoned CA2248657A1 (en) 1996-03-11 1997-03-10 Peptides with increased binding affinity for hla molecules

Country Status (9)

Country Link
EP (1) EP0914142B9 (https=)
JP (2) JP2001504799A (https=)
CN (1) CN1225590A (https=)
AT (1) ATE511849T1 (https=)
AU (1) AU2203797A (https=)
BR (1) BR9708161A (https=)
CA (1) CA2248657A1 (https=)
ES (1) ES2367640T3 (https=)
WO (1) WO1997033602A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
CA2323632A1 (en) * 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
WO2000044775A2 (en) * 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
EP1230268B1 (en) * 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
DK1299727T3 (da) 2000-07-12 2009-06-15 Agensys Inc Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
WO2002060953A2 (en) * 2000-12-15 2002-08-08 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158860A0 (en) * 2001-05-15 2004-05-12 Agensys Inc Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
EP1495322A4 (en) * 2002-04-05 2006-09-06 Epimmune Inc HETEROKLITIC ANALOGUES AND ASSOCIATED METHODS
JP2005535627A (ja) * 2002-06-25 2005-11-24 シティ・オブ・ホープ アジュバント不含ペプチド・ワクチン
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1565200A4 (en) 2002-11-27 2009-06-24 Agensys Inc NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
JP2007524361A (ja) 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
CN101370517B (zh) * 2006-01-23 2012-12-05 株式会社绿多肽 来源于c型肝炎病毒的肽
EP1982992B1 (en) 2006-02-07 2010-10-27 NEC Corporation Hla-binding peptide, precursor thereof, dna fragment encoding the same and recombinant vector
EP2085474A4 (en) 2006-10-12 2010-12-01 Nec Corp HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
EP2391635B1 (en) * 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
AU2012258603A1 (en) 2011-05-26 2014-01-16 Geneius Biotechnology, Inc. Modulated immunodominance therapy
CN110651189B (zh) 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US20050271676A1 (en) * 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
EP0728764A4 (en) * 1993-10-19 1999-01-20 Ajinomoto Kk PEPTIDE THE IMMUNE RESPONSE TO HIV UNDUCED AND MEDICINAL PRODUCTS CONTAINING THE PREVENTION OR TREATMENT OF AIDS

Also Published As

Publication number Publication date
WO1997033602A1 (en) 1997-09-18
ES2367640T3 (es) 2011-11-07
EP0914142A1 (en) 1999-05-12
ATE511849T1 (de) 2011-06-15
CN1225590A (zh) 1999-08-11
BR9708161A (pt) 1999-07-27
AU2203797A (en) 1997-10-01
JP2001504799A (ja) 2001-04-10
EP0914142A4 (en) 2004-06-23
EP0914142B9 (en) 2012-01-04
EP0914142B1 (en) 2011-06-08
JP2009108097A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
EP0914142B1 (en) Peptides with increased binding affinity for at least three hla-a3-like molecules
WO1997033602A9 (en) Peptides with increased binding affinity for hla molecules
EP1917970B1 (en) Hla binding peptides and their uses
EP0907370B1 (en) Hla-a2.1 binding peptides and their uses
CA2248659A1 (en) Hla binding peptides and their uses
AU2000232427A1 (en) HLA binding peptides and their uses
US20020177694A1 (en) Hla binding peptides and their uses
AU2002243730B2 (en) Subunit vaccines with A2 supermotifs
AU2002243730A1 (en) Subunit vaccines with A2 supermotifs
US20040157273A1 (en) Subunit vaccines with a2 supermotifs
JP2004517609A (ja) Ｈｌａ−ａ２．１結合ペプチドおよびそれらの用途
EP1320377B1 (en) Hla binding peptides and their uses
JP2002518346A (ja) Ｈｌａ結合ペプチドおよびそれらの用途
EP1767542B1 (en) HLA-A2.1 binding peptides and their uses
MXPA98007512A (en) Peptides with increased affinity by molecules from locus to leucocitus huma
CA2421448A1 (en) Hla binding peptides and their uses
AU4754899A (en) HLA Binding peptides and their uses
MXPA98007702A (en) Location peptides of locus hla-a2.1 and its u

Legal Events

Date Code Title Description
EEER Examination request
FZDC Discontinued application reinstated
FZDE Discontinued